Immune Response Affecting Drug Patents (Class 514/885)
-
Patent number: 5308837Abstract: The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-amine substituted adenosine analogs.Type: GrantFiled: November 12, 1992Date of Patent: May 3, 1994Assignee: Merrell Dow Pharmaceuticals Inc.Inventor: Terry L. Bowlin
-
Patent number: 5308612Abstract: The uses of polystyrenesulfonate and related compounds to inhibit HIV Tat function/replication and for therapy of HIV/AIDS.Type: GrantFiled: August 12, 1992Date of Patent: May 3, 1994Assignee: Blue Marble Research, Inc.Inventor: Jung J. Lee
-
Patent number: 5302611Abstract: Tetra- and pentacyclic oxindole alkaloids, in particular the alloisopteropodine, isomer A, a pentacyclic oxindole alkaloid, are suitable for the unspecific stimulation of the immunologic system, which has been proved by a substantial percental phagocytosis increase in the granulocytic test according to BRANDT (in vitro), a substantial percental increase of the CL-response in the chemiluminescence test (in vitro) and a high increase of the phagocytosis activity of tissue macrophages of the reticoloendothelial system in the carbon-clearence-test (CCT) according to BIOZZI.Type: GrantFiled: September 30, 1992Date of Patent: April 12, 1994Assignee: Klaus KeplingerInventors: Klaus Keplinger, Dietmar Keplinger
-
Patent number: 5294443Abstract: The present invention involves the use of Tripterygium Wilfordii Hook F extracts in the treatment of rheumatoid arthritis. An alcohol extract of this plant (T2) inhibited antigen- and mitogen-stimulated proliferation of T cells and B cells, cell cycle progression, interleukin-2 (IL-2) production by T cells, immunoglobulin production by B cells and interleukin-2 mRNA production. T2 did not affect IL-2 receptor expression by T cells, IL-1 production by monocytes, the capacity of monocytes to present antigen, or signaling pathways. Inhibition could not be accounted for by nonspecific toxicity. These results support the conclusion that T2 exerts a powerful suppressive effect on human immune responses. Suppressing autoinnune disease is a most preferred embodiment of this invention.Type: GrantFiled: April 3, 1992Date of Patent: March 15, 1994Assignee: Board of Regents, The University of Texas SystemInventors: Peter E. Lipsky, Xue-Lian Tao
-
Patent number: 5292513Abstract: A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable, biocompatible particle to prime macrophages for enhanced oxidative response and bacterial killing. Patients can have the benefits of primed macrophages in one to four days, and experiments have demonstrated over a 100-fold increase in oxidative potential within this time period. The oxidative response and killing potential is non-immunospecific, meaning not one organism, not a vaccine, and broadly applicable simultaneously to bacteria and viruses as well as tumor cells. The effects have been demonstrated to have a seven day duration indicating non-tissue toxic residual effects and potential for repeated use at monthly intervals.Type: GrantFiled: May 18, 1992Date of Patent: March 8, 1994Assignee: Anthony G. GristinaInventors: Anthony G. Gristina, Quentin N. Myrvik
-
Patent number: 5292505Abstract: Sulphated vinyl polymers such as sulphated polyvinylalcohol, sulphated copolymers of (meth)acrylic acid and vinylalcohol, and pharmaceutically acceptable salts thereof, have an antiviral effect against human immunodeficiency virus and may therefore be used as a therapeutic agent for treating retrovirus infections like AIDS and AIDS-related diseases. Their antiviral activity is apparently based on inhibition of virus adsorption; their inhibitory effect on giant cell formation is stronger than that of dextran sulphate.Type: GrantFiled: January 15, 1992Date of Patent: March 8, 1994Assignees: Stichting Rega VZW, Richter Gedeon Vegyeszeti Gyar RTInventors: Masanori Baba, Erik D. A. De Clercq, Sandor Gorog, Miklos Low, Miklos Nagy, Sandorne Gyorgyi
-
Patent number: 5292730Abstract: Alzheimer's disease and immune deficiency disorders may be effectively treated by administering a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.by administering a therapeutic amount of a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.Type: GrantFiled: July 31, 1992Date of Patent: March 8, 1994Assignee: Humanetics CorporationInventor: Henry A. Lardy
-
Patent number: 5290783Abstract: A method for suppressing an immune response in a mammal by treating the mammal with an effective amount of spiperone derivative that is without significant neuroleptic effect due to decreased binding to serotonin and/or dopamine receptors as compared with unmodified or uncomplexed spiperone, or due to topical application which maximizes local immunosuppression while limiting systemic absorption and neuroleptic effects. The spiperone derivatives are capable of inhibiting classic contact hypersensitivity reactions.Type: GrantFiled: December 27, 1991Date of Patent: March 1, 1994Assignee: Beth Israel Hospital AssociationInventors: Richard J. Sharpe, Kenenth A. Arndt, Stephen J. Galli
-
Patent number: 5290571Abstract: The present invention is concerned with a whey protein composition comprising a suitable concentration of whey protein concentrate wherein the whey protein concentrate contains proteins which are present in an essentially undenatured state and wherein the biological activity of the whey protein concentrate is dependent on the overall amino acid and small peptides pattern resulting from the contribution of all its protein components and a method of producing said whey protein composition. The invention also relates to several applications of said composition.Type: GrantFiled: October 4, 1989Date of Patent: March 1, 1994Assignee: Immunotec Research Corporation, Ltd.Inventors: Gustavo Bounous, Phil Gold, Patricia A. L. Kongshavn
-
Patent number: 5290540Abstract: A method of treating pneumonia caused by a microorganism by administering directly into the lower respiratory tract of a host an amount of an anti-inflammatory agent effective to reduce inflammation is provided. The method may further include administering to a host an amount of an anti-infectious agent with activity against the microorganism effective to reduce the concentration of the microorganism.Type: GrantFiled: May 1, 1992Date of Patent: March 1, 1994Assignee: Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Gregory A. Prince, Val G. Hemming
-
Patent number: 5288704Abstract: A pharmaceutcial composition is provided for use in the prevention or treatment of viral infections caused by enveloped viruses. The composition comprises a fibroblast growth factor, a sulfated polysaccharide with antiviral activity, and one or more pharmaceutically acceptable carriers. The fibroblast growth factor may be a basic fibroblast growth factor or an analogue thereof, and the polysaccharide may be a carrageenan, heparin, dextran sulfate, pentosan polysulfate or a sulfated polysaccharides produced by marine algae belonging to the class of Rhodophyceae.Type: GrantFiled: January 31, 1992Date of Patent: February 22, 1994Assignee: Farmitalia Carlo Erba S.R.L.Inventors: Domenico Ungheri, Luisa Garofano, Carlo Battistini, Paolo Carminati, Guy Mazue
-
Patent number: 5284826Abstract: Hydroxy-substituted [(D)Ser].sup.8 -Ciclosporin derivatives, particularly [O-(2-hydroxyethyl)(D)Ser].sup.8 -Ciclosporin, have advantageous pharmacological properties and are useful as immunosuppressants, for example in the treatment of transplant rejection and autoimmune diseases.Type: GrantFiled: August 27, 1992Date of Patent: February 8, 1994Assignee: Sandoz Ltd.Inventor: Marcel K. Eberle
-
Patent number: 5284656Abstract: Granulocyte-colony stimulating factor (G-CSF) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration in accordance with this invention results in significant elevation of the neutrophil levels that compares favorably with delivery by subcutaneous injection. G-CSF can be administered in this manner to medically treat neutropenia, as well as to combat or prevent infections.Type: GrantFiled: September 29, 1992Date of Patent: February 8, 1994Assignee: Amgen Inc.Inventors: Robert M. Platz, Mark A. Winters, Colin G. Pitt
-
Patent number: 5283066Abstract: Disclosed is a method of stimulating an immune response by using a hapten. Haptens are adhered onto a solid phase support to form a complex. This complex can stimulate an immune response of an animal and the animal's lymphocytes. The solid phase supports usable in the method preferably are membranes, latex particles or microparticle beads of hydrophilic cellulose mixed ester, nitrocellulose, cellulose acetate, nylon, polyvinylidone, vinylbenzyl chloromethyl styrene, polyacrolein, a ahydrophobic, polytetrafluoroethylene, polystyrene and silica gel.Type: GrantFiled: February 19, 1992Date of Patent: February 1, 1994Assignee: Development Center for BiotechnologyInventors: Jiuan J. Liu, Chun-Chieh Wang, Yuang-Ling Hwang, Tong H. Chang
-
Patent number: 5283330Abstract: The present invention is directed to the compound 1,2-benzo-8-(D,L alanyl)-3-phenoxazone nitrate and to the method for preparing this compound.Type: GrantFiled: September 11, 1992Date of Patent: February 1, 1994Inventor: Kantilal G. Bhansali
-
Patent number: 5278183Abstract: A pharmaceutical composition for the treatment of autoimmune diseases comprising an effective amount of a compound of formulaA--CH.sub.2 --O--CRR'--COOR"' (I)whereA is the nucleus of 1-benzyl-indazol-3-yl,R and R', the same or different from each other, are H or an alkyl having from 1 to 5 carbon atoms,R"' is H or an alkyl having from 1 to 4 carbon atoms,or, when R"' is H, of a salt thereof with organic or inorganic pharmaceutically acceptable bases.Type: GrantFiled: April 14, 1992Date of Patent: January 11, 1994Assignee: Instituto Ricerca Francesco Angelini S.p.A.Inventor: Bruno Silvestrini
-
Patent number: 5278173Abstract: A method for inhibiting the activity of human immunodeficiency virus (HIV) in vivo comprises administering to a human host an antimalarial drug, which is capable of exhibiting a protective effect, a curative effect, or of preventing transmission of malaria in humans. The antimalarial drug is selected from the group consisting of(a) alkaloids;(b) 9-amino-acridines;(c) 4-aminoquinolines;(d) 8-aminoquinolines;(e) biguanides;(f) dihyrofolate reductase inhibitors;(g) sulfones;(h) sulfonamides;(i) mefloquine;(i) halofantrine;(k) hydroxyanilino-benzo-naphtyridines; and(l) sesquiterpene lactones.The antimalarial drug is administered to the human in an amount sufficient to prevent or at least inhibit infection of T lymphocytes by HIV in vivo or to prevent or at least inhibit replication of HIV in vivo.Type: GrantFiled: December 10, 1992Date of Patent: January 11, 1994Inventor: Michael H. Davis
-
Patent number: 5276016Abstract: Short peptide of the formula:R.sup.a -Ser-Thr-Thr-Thr-Asn-Tyr-R.sup.b (I)where R.sup.a represents an amino terminal residue Ala- or D-Ala and R.sup.b represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II):R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 (II)whereR.sup.1 is an amino terminal residue Thr-, Ser-, Asn-,Leu-,Ile-,Arg- or Glu-R.sup.2 is Thr, Ser or AspR.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or TrpR.sup.4 is Tyr andR.sup.5 is a carboxy terminal amino group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals,or a physiologically acceptable salt thereof.Such peptides bind to T4 receptors are useful in preventing viral infectivity by viruses which bind to the T4 receptors.Type: GrantFiled: August 16, 1990Date of Patent: January 4, 1994Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Candace B. Pert, Michael R. Ruff, William L. Farrar
-
Patent number: 5273747Abstract: The present invention relates to new therapeutic uses of lipophilic extracts of Commiphora mukul, prepared from exudate of said plant, as well as the preparation of pure compounds or highly standardized fractions thereof as active ingredients. The extracts, the fractions thereof or the single pure active ingredients isolated therefrom proved to be useful in the treatment of inflammations, both of allergic origin and not, concerning skin and external mucosae, and in the symptomatic treatment of benign prostatic hypertrophy and in the resolutive treatment of acne.Type: GrantFiled: May 14, 1992Date of Patent: December 28, 1993Assignee: Indena S.P.A.Inventors: Ezio Bombardelli, Michele Spelta
-
Patent number: 5268365Abstract: The invention provides a method of stimulating the immune function with the aid of a nucleobase source, the use of nucleobase sources for immunostimulation and compositions comprising such nucleobase sources. The invention also provides the use of nuclobase source for the maintenance of the immune function in the presense of protein depletion or protein starvation.Type: GrantFiled: September 27, 1991Date of Patent: December 7, 1993Inventors: Frederick B. Rudolph, Charles T. Van Buren
-
Patent number: 5266564Abstract: There is described the production of a pharmaceutical composition for the eatment of autoimmune diseases, whereby multiple sclerosis is excluded. As active materials, there are thereby used compounds of the general formula I ##STR1## in which R.sub.1 represents alkyl with 12 to 18 carbon atoms, R.sub.2 alkyl with 1 to 8 carbon atoms and R.sub.3 H or alkyl with 1 to 3 carbon atoms.Type: GrantFiled: December 23, 1991Date of Patent: November 30, 1993Assignee: Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V.Inventors: Manuel Modolell, Gerhard Munder
-
Patent number: 5262157Abstract: Pneumocystis carinii pneumonia may be prevented in a subject susceptible to infection by Pneumocystis carinii by administering to the subject an amount of a pentamidine in aerosol form effective to prevent infection by Pneumocystis carinii and thus prevent Pneumocystis carinii pneumonia. Also, this invention provides a composition for the prevention of Pneumocystis carinii pneumonia which comprises an amount of a pentamidine effective to prevent infection by Pneumocystis carinii and thus prevent Pneumocystis carinii pneumonia in aerosol form and a pharmaceutically acceptable carrier.Type: GrantFiled: December 20, 1988Date of Patent: November 16, 1993Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Edward M. Bernard, Donald Armstrong
-
Patent number: 5262424Abstract: A compound of the structure ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen or --CONHSO.sub.2 --Ar; andAr is phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, quinoxalyl, thienyl, thionaphthyl, furyl, benzofuryl, benzodioxyl, benzoxazolyl, benzoisoxazolyl, or benzodioxolyl; wherein the Ar group may be optionally mono-, di-, or tri-substituted; with the proviso that R.sup.1 and R.sup.2 are not both hydrogen;or a pharmaceutically acceptable salt thereof which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host vs. graft disease, autoimmune diseases and diseases of inflammation; by virtue of its antitumor activity is useful in treating solid tumors; and by virtue of its antifungal activity is useful in treating fungal infections.Type: GrantFiled: November 17, 1992Date of Patent: November 16, 1993Assignee: American Home Products CorporationInventor: Wenling Kao
-
Patent number: 5258518Abstract: 2-Substituted tertiary carbinol derivatives of deoxynojirimycin are disclosed having the formula ##STR1## wherein R.sub.4 =an alkyl, vinyl, alkenyl, alkynyl, aryl, aralkyl, alkenylalkyl, alkylnylalkyl or CH.sub.2 Y substituent having from about 1 to 10 carbon atoms;Y=OR', SR', NR'R', or N.sub.3 ;R=H or CH.sub.3 ; andR=H or an alkyl, aralkyl, alkenylalkyl, alkynylalkyl, aralkenyl, aralkynyl or hydroxyalkyl substituent, having from about 1 to 18 carbon atoms, provided that no carbon unsaturated bond is directly attached to nitrogen.These compounds have useful antiviral activity as demonstrated against lentivirus.Type: GrantFiled: April 1, 1992Date of Patent: November 2, 1993Assignee: G. D. Searle & Co.Inventors: Ish K. Khanna, Richard A. Mueller, Richard M. Weier
-
Patent number: 5258407Abstract: Certain 3,4-disubstituted phenols and pharmaceutically acceptable salts thereof are provided which mimic IL-1 activity by inducing IL-2 synthesis and subsequent IL-2 receptor expression. Specifically, the invention provides compounds of Formula I and acid addition salts thereof: ##STR1## wherein Y is ##STR2## NHSO.sub.2 or SO.sub.2 NH where R.sup.4 is H; Z is --O--, --NH--, --NR--, --S--, or other heteroatoms capable of hydrogen bonding with R.sup.4 to give a preferred conformation;R is alkyl;R.sup.1 is --OH;R.sup.2 is H, alkyl, cycloalkyl, aralkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted nitrogen heterocyclic group having 4 to 5 nuclear carbon atoms; andR.sup.3 is a lipophilic moiety.Type: GrantFiled: December 31, 1991Date of Patent: November 2, 1993Assignee: Sterling Winthrop Inc.Inventors: William N. Washburn, Barbara B. Lussier, Carl B. Illig, Lee H. Latimer
-
Patent number: 5256641Abstract: This invention relates to methods of facilitating the entry of peptides into cells and targeting such peptides to specific organelles within the cell. The invention provides methods for delivering and specific targeting of antigenically-active peptides to cells for the specific production of immunological reactivity against such peptides, as well as compositions and pharmaceutical compositions of matter comprising such peptides. This invention thereby provides improved methods for vaccine production and in vivo vaccination against pathogenic microorganisms. Methods for alleviating autoimmune disease and ameliorating tissue and organ transplant rejection using such conjugates are also provided.Type: GrantFiled: July 9, 1992Date of Patent: October 26, 1993Assignee: State of OregonInventors: Milton B. Yatvin, Michael H. B. Stowell, Miroslav Malkovsky
-
Patent number: 5256647Abstract: This invention provides compositions comprising a physiologically-active agent and a compound having the structural formula ##STR1## wherein X may represent sulfur or two hydrogen atoms; R' is H or a lower alkyl group having 1-4 carbon atoms; m is 2-6; n is 0-18 and R is --CH.sub.3, ##STR2## wherein R" is H or halogen, in an amount effective to enhance the penetration of the physiologically-active agent through the skin or other membrane of the body of an animal.Type: GrantFiled: November 13, 1990Date of Patent: October 26, 1993Assignee: Whitby Research, Inc.Inventors: Gevork Minaskanian, James V. Peck, Eric L. Nelson
-
Patent number: 5252612Abstract: Described is a new immunosuppressant, L-683,756, a bisdemethylated, ring rearranged derivative of L-683,590, produced under fermentation conditions utilizing the microorganism, Actinoplanacete sp. (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: June 24, 1992Date of Patent: October 12, 1993Assignee: Merck & Co., Inc.Inventors: Byron H. Arison, Edward S. Inamine, Shieh-Shung T. Chen, Linda S. Wicker
-
Patent number: 5248667Abstract: Peptides previously disclosed as useful for preventing HIV from binding to cell binding sites have now been shown to have thymoleptic qualities and to be useful for tretment of psoriasis in patients who lack antibodies against HIV.Type: GrantFiled: July 18, 1991Date of Patent: September 28, 1993Assignee: The United States of America as represented by the Secretary of the Department of Health & Human ServicesInventors: Peter Bridge, Frederick K. Goodwin
-
Patent number: 5248502Abstract: A method of reducing the allergenicity of psyllium seed husk. Psyllium seed husk is treated with a alkaline solution at a temperature and for a time sufficient to reduce the allergenicity of the psyllium seed husk.Type: GrantFiled: November 8, 1991Date of Patent: September 28, 1993Assignee: Kellogg CompanyInventor: Louis I. Ndife
-
Patent number: 5246924Abstract: The present invention relates to a composition for, and a method of, treating a hepatitis viral infection in a subject using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil [FEAU].Type: GrantFiled: May 6, 1991Date of Patent: September 21, 1993Assignees: Sloan-Kettering Institute for Cancer Research, Institut National de la Sante et de la Recherche MedicaleInventors: Jack J. Fox, Kyoichi A. Watanabe, Carlos Lopez, Christian G. Trepo
-
Patent number: 5244904Abstract: This invention is directed to a indole derivative represented by the general formula (1) ##STR1## wherein R.sub.1 stands for alkyl of 1 to 5 carbon atoms, cycloalkylalkyl of 4 to 7 carbon atoms, cycloalkenylalkyl of 5 to 7 carbon atoms, aralkyl of 7 to 14 carbon atoms, trans-alkenyl of 4 to 5 carbon atoms, allyl, furanyl-2-ylalkyl of 1 to 5 carbon atoms, thienyl-2-ylalkyl of 1 to 5 carbon atoms, vinyloxycarbonyl, trichloroethoxycarbonyl, benzyloxycarbonyl, alkanoyl of 1 to 5 carbon atoms, aralkylcarbonyl of 7 to 14 carbon atoms, 2-furoyl, thiophene-2-carbonyl, cycloalkylcarbonyl of 4 to 7 carbon atoms, alkenylcarbonyl of 3 to 8 carbon atoms, or anisoyl, R.sub.2 for a hydrogen atoms, alkyl of 1 to 3 carbon atoms, benzyl, or alkanoyl of 1 to 5 carbon atoms, R.sub.3 for a hydrogen atoms, a fluorine atom, a chlorine atom, a bromine atom, nitro, or alkyl of 1 to 5 carbon atoms, R.sub.4 for a hydrogen atom, alkyl of 1 to 5 carbon atoms, benzyl, or phenyl, and R.sub.Type: GrantFiled: January 29, 1992Date of Patent: September 14, 1993Assignee: Toray Industries, Inc.Inventors: Hiroshi Nagase, Akira Mizusuna, Yoshihiro Onoda, Koji Kawai, Shu Matsumoto, Takashi Endo
-
Patent number: 5244899Abstract: The compounds of this invention are azabicyclic and azatricyclic amides represented by the formula: ##STR1## wherein: R.sub.1 and R.sub.2 are the same or different members of the group consisting of halo, phenyl, substituted phenyl and a ##STR2## group wherein n, m and p are independently an integer of from 1 to 8 provided that n+m+p is equal to or less than 10; X is thio, sulfinyl or sulfonyl; Alk is straight or branched chain lower alkylene; R.sub.3 is selected from the group consisting of a azabicycloalkylamino, azatricycloalkylamino or dicycloalkylamino. The compounds are useful as anti-inflammatory and anti-allergy agents.Type: GrantFiled: July 29, 1992Date of Patent: September 14, 1993Assignee: G. D. Searle and Co.Inventors: Richard A. Mueller, Richard A. Partis, James R. Deason
-
Patent number: 5244902Abstract: A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with immune response in a human or other mammal, that includes topical application of an effective amount of spiperone or a spiperone derivative or its pharmaceutically acceptable salt, in a pharmaceutically-acceptable diluent or carrier for topical application.Type: GrantFiled: February 5, 1992Date of Patent: September 14, 1993Assignee: Beth Israel Hospital AssociationInventors: Richard J. Sharpe, Kenneth A. Arndt, Stephen J. Galli
-
Patent number: 5242687Abstract: Specific and nonspecific immunomodulation, enhancement of cellular engraftment, and modulation of nonimmune cells are achieved by using various membrane-binding and soluble CD8 compositions.Type: GrantFiled: April 25, 1991Date of Patent: September 7, 1993Assignee: TKB Associates Limited PartnershipInventors: Mark L. Tykocinski, David R. Kaplan
-
Patent number: 5236899Abstract: Cyclosporin analogs containing a MeAla or MeAbu residue at the 6-position of the cyclic undecapeptide have been discovered to sensitize multidrug resistant cells to certain chemotherapeutic agents. These cyclosporin analogs have also been shown to increase the sensitivity of cells already susceptible to the chemotherapeutic agents. In addition, these cyclosporin A analogs lack the nephrotoxic and immunosuppressive activity of cyclosporin A.Type: GrantFiled: August 23, 1991Date of Patent: August 17, 1993Assignee: Merck & Co., Inc.Inventor: Philippe L. Durette
-
Patent number: 5236905Abstract: The use of TGF-.beta. to inhibit HIV infection and/or replication is described. Both mature and precursor forms of TGF-.beta. are efficacious in inhibiting production of HIV. The TGF-.beta. used to inhibit HIV may be obtained from natural sources or may be produced by recombinant DNA or chemical synthetic techniques. TGF-.beta.1 and/or TGF-.beta.2 may be used. Additionally, hybrid TGF-.beta.1/.beta.2 molecules may also be utilized.Type: GrantFiled: August 25, 1988Date of Patent: August 17, 1993Assignee: OncogenInventors: Vera Brankovan, Mario N. Lioubin, Anthony F. Purchio
-
Patent number: 5234683Abstract: The present invention relates to biologically-active copolymers and to compounds that can be safely used to cause the thymus of an animal or human to increase in size, thereby replenishing the T-lymphocyte population. When injected into an animal or human with an antigen, certain of the biologically-active copolymers cause immunosuppression to the antigen.When injected into poultry, certain of the biologically-active copolymers modulate immune responsiveness. The biologically active copolymers are also useful as growth promoters for animals. Compounds within the biologically-active copolymers of the present invention are effective tumoricidal agents. At low concentration, certain of the biologically-active copolymers can cause dedifferentiated cells to differentiate.The biologically-active copolymer of the present invention is a safe and non-toxic formulation that can effectively be administered to animals or humans.Type: GrantFiled: June 12, 1991Date of Patent: August 10, 1993Assignee: Emory UniversityInventors: Robert L. Hunter, William L. Ragland
-
Patent number: 5231085Abstract: The invention provides immunostimulatory compositions comprising an aggregate immunostimulatory amount ofa) a compound associated with the synthesis of polyamines,b) a nucleobase source,c) omega-3 polyunsaturated fatty acids, andd) omega-6 polyunsaturated fatty acidsthe use of such compositions and their manufacture.Type: GrantFiled: February 19, 1992Date of Patent: July 27, 1993Assignee: Sandoz Ltd.Inventors: J. Wesley Alexander, Vigen K. Babayan, George L. Blackburn, Frank B. Cerra, John Daly, Mitchell T. Gersovitz, John E. Kinsella, Jerome J. LiCari, Frederick Rudolph, Charles T. Van Buren
-
Patent number: 5227369Abstract: The present invention provides pharmaceutical compositions and methods for treating demyelinating diseases. The compositions comprise a blocking agent which inhibits LHR-mediated binding of leukocytes to myelin.Type: GrantFiled: July 11, 1991Date of Patent: July 13, 1993Assignee: The Regents of the University of CaliforniaInventors: Steven Rosen, Kun Huang, Mark Singer, Joyce Geoffroy
-
Patent number: 5223258Abstract: An antiviral medicinal composition having spent liquor from kraft pulping and/or processed products thereof (kraft lignin, sulfomethylated and/or sulfopropylated kraft lignin) as major constituents, are effective agents in therapeutic and/or preventive methods against AIDS.Type: GrantFiled: January 11, 1990Date of Patent: June 29, 1993Assignee: Sanyo-Kokusaku Pulp Co., Ltd.Inventors: Makoto Machida, Makoto Yashiro, Kunichika Murakami
-
Patent number: 5219851Abstract: The invention concerns novel renin-inhibitory compounds which contain a tetrahydroisoquinoline or similar heterocycle at the P.sub.3 position. These are useful for treating hypertension, congestive heart failure, glaucoma, hyperaldosteronism, and diseases caused by retroviruses including HTLV-I, -II and -III. Processes for preparing the compounds, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, or hyperaldosteronism.Type: GrantFiled: March 5, 1991Date of Patent: June 15, 1993Assignee: Warner-Lambert CompanyInventors: Harriet W. Hamilton, William C. Patt
-
Patent number: 5211945Abstract: This invention relates to methods for modulating the effects of TNF and IL-1, both the deleterious and the therapeutical effect of these cytokines. In case of deleterious effects, the invention provides methods for modulating the deleterious effect of TNF and/or IL-1 in mammals, by administering to a mammal sub-deleterious amounts of TNF and/or IL-1. The TNF and/or IL-1 to be modulated may be endogenous, i.e. generated in the organism in severe cases in amounts deleterious to the organism, or exogenously administered to a patient in amounts which are potentially deleterious. The compositions of the invention comprise effective amounts of TNF and/or IL-1 with at least one pharmaceutically acceptable carrier. The invention also relates to methods for monitoring the modulation of the TNF effect in patients treated with TNF and/or IL-1.Type: GrantFiled: September 9, 1987Date of Patent: May 18, 1993Assignee: Yeda Research and Development Co. Ltd.Inventors: David Wallach, Helmut Holtmann
-
Patent number: 5206008Abstract: The present invention provides an improved means for regulating the immune response, for ameliorating effects of stress, and for avoiding untoward effects of chemotherapy or exposure to irradiation by administration of androstenediol (AED) and androstenetriol (AET). The improved means of regulating immune response can be utilized in treating infectious diseases and immune diseases such as diabetes and chronic fatigue syndrome, both diseases now considered to be immune response related syndromes.Type: GrantFiled: August 2, 1991Date of Patent: April 27, 1993Assignee: Virginia Commonwealth UniversityInventor: Roger Loria
-
Patent number: 5206223Abstract: Heparanase activity in a patient may be inhibited by administering an effective heparanase-inhibiting amount of heparin or an effective chemically modified derivative of heparin which inhibits heparanase activity. Such derivatives are preferably N-desulfated, N-acetylated heparin or O-desulfated, N-acetylated heparin. By means of this invention, allograft rejection may be prevented or delayed and autoimmune diseases such as arthritis may be alleviated and treated.Type: GrantFiled: September 17, 1990Date of Patent: April 27, 1993Assignee: Yeda Research and Development Co. Ltd.Inventors: Israel Vlodavsky, Amiram Eldor, Yaakov Naparstek, Irun Cohen
-
Patent number: 5204101Abstract: A method and composition for treating Acquired Immunodeficiency Virus infections with a composition formulated from dried powders of Phytolacca americana, Rumex acetosella and Rutacea liminonia. The resulting composition acts as an anti-viral agent.Type: GrantFiled: October 15, 1991Date of Patent: April 20, 1993Inventors: Thomas W. Stubblefield, Betty J. Cothran
-
Patent number: 5200400Abstract: Method for inhibiting acute rejection of a transplanted organ or tissue by a recipient mammal that includes the steps of administering to the mammal a compound which causes selective sensitization of the alloreactive lymphocytes of the transplant recipient that are involved in the rejection process to a toxin; and exposing the mammal to the toxin to selectively destroy the sensitized alloreactive lymphocytes to a greater extent than non-sensitized cells of the mammal. This method induces donor specific tolerance in the transplant recipient, i.e., acceptance of the new organ or tissue without suppression of the rest of the recipient's normal immune system.Type: GrantFiled: July 12, 1991Date of Patent: April 6, 1993Assignee: New England Deaconess Hospital CorporationInventors: Kenichi Teramoto, Melvin E. Clouse
-
Patent number: 5198417Abstract: Disclosed herein is the treatment of patients suffering from AIDS-type disease with erythropoietin alone or together with a colony stimulating factor, and/or an anti-viral agent and/or IL-2.Type: GrantFiled: November 7, 1989Date of Patent: March 30, 1993Assignee: Genetics Institute, Inc.Inventor: Robert E. Donahue
-
Patent number: 5198334Abstract: Leucinol, phenylalaninol and benzamide protect against loss of Natural Killer activity when Peripheral Blood Mononuclear Cells are treated with an ester of an amino acid or dipeptide or an amide of an amino acid prior to incubation with IL-2 to generate Lymphokine-Activated Killer activity.Type: GrantFiled: July 21, 1989Date of Patent: March 30, 1993Assignee: Terumo CorporationInventor: Kam H. Leung
-
Patent number: 5196430Abstract: A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branch alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.Type: GrantFiled: September 18, 1991Date of Patent: March 23, 1993Assignees: Hoechst-Roussel Pharmaceuticals Inc., University of Virginia Alumni Patents FoundationInventors: Gerald L. Mandell, Gail W. Sullivan, William J. Novick